Indian Journal of Nuclear Medicine
Home | About IJNM | Search | Current Issue | Past Issues | Instructions | Ahead of Print | Online submissionLogin 
Indian Journal of Nuclear Medicine
  Editorial Board | Subscribe | Advertise | Contact
Users Online: 282 Print this page  Email this page Small font size Default font size Increase font size


 
 Table of Contents     
ORIGINAL ARTICLE
Year : 2015  |  Volume : 30  |  Issue : 3  |  Page : 227-232  

Iodine-131 avid distant metastasis in differentiated thyroid cancer: An initial institutional experience from the northern part of India


1 Department of Nuclear Medicine, Sher i Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India
2 Department of Radiotherapy, Sher i Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India

Date of Web Publication11-Jun-2015

Correspondence Address:
Shoukat Hussain Khan
Department of Nuclear Medicine, Sher i Kashmir Institute of Medical Sciences, Soura, Srinagar - 190 011, Jammu and Kashmir
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0972-3919.158530

Rights and Permissions
   Abstract 

Objective: The aim of the study was to study the clinical profile in patients of differentiated thyroid cancer (DTC) with Iodine-131 avid distant metastasis at presentation. The study also attempted to evaluate factors influencing survival among these patients. Material and Methods: The cohort includes 35 patients (26 Female, 9 Male) studied retrospectively and prospectively over a period of 5 years at the Sher-I-Kashmir Institute of Medical Sciences, Srinagar, India. Results: The five years cause specific survival among patients of DTC with distant metastasis in the study group was 74.3%. The mean age at presentation was 41.4 years with female patients outnumbering the male patients in a ratio of 5:1.Papillary histopathology was the commonest in 65.7% followed by Follicular in 31.4% and poorly differentiated cancer in 2.9% of patients.31.4% 0f patients presented with relatively advanced AJC/UICC tumor stage of T3-T4. Bone was the commonest site of metastasis in 42.85% of patients followed by lung in 40% 0f patients. 82.9% of patients had only single organ metastasis. Therapeutic Radioiodine was administered in 31 (88.6%) patients. On univariate analysis of various factors that may be influencing the cause specific survival at 5 years, age ≥ 45 years, T3-T4 tumor stage, regional lymph node metastasis, follicular histopathology and non administration of radioiodine revealed significant (P<0.05) association with a poor 5 year survival. However multivariate analysis identified advanced tumor stage (T3-T4) and non administration of radioiodine to be the only independent factors associated with poor survival. Conclusion: Patients of differentiated thyroid cancer with distant metastasis having advanced tumor stage (T3-T4) and those in whom therapeutic radioiodine (I-131) is not administered seem to have an unfavorable prognosis in terms of a 5 years cause specific survival.

Keywords: Cause-specific survival, differentiated thyroid cancer, distant metastasis, radioiodine


How to cite this article:
Khan SH, Hassan Mu, Bhau RS. Iodine-131 avid distant metastasis in differentiated thyroid cancer: An initial institutional experience from the northern part of India. Indian J Nucl Med 2015;30:227-32

How to cite this URL:
Khan SH, Hassan Mu, Bhau RS. Iodine-131 avid distant metastasis in differentiated thyroid cancer: An initial institutional experience from the northern part of India. Indian J Nucl Med [serial online] 2015 [cited 2021 Jun 23];30:227-32. Available from: https://www.ijnm.in/text.asp?2015/30/3/227/158530


   Introduction Top


Over the years, the incidence of differentiated thyroid cancer (DTC) has been reported to be increasing. [1],[2],[3] By and large most of the guidelines advocate total thyroidectomy with lymph node dissection, followed by thyroid remnant ablation radioactive iodine-131 (I-131) and thyroxine suppression. [4],[5] The follow-up strategy in addition to routine clinical examination includes monitoring by serum thyroglobulin (Tg) and high-resolution neck ultrasonography in select cases. Despite an overall favorable prognosis in patients of DTC, 5-23% of patients have distant metastasis, which confers on them a relative poor prognosis despite of adequate treatment. Lately flourine-18 flourodeoxy glucose positron emission tomography (F-18 FDG PET) in patients with elevated serum Tg but negative I-131 scan (thyroglobulin elevated negative iodine scintigraphy [TENIS]) has helped in identifying patients of symptomatic and/or progressive metastatic DTC amenable to surgical excision or treatment with alternative treatment modalities such as radiotherapy, tyrosine kinase inhibiting drugs, dedifferentiating drugs, etc. [6] Published data on variables influencing the prognostic outcome in patients of DTC with distant metastasis is scarce and based on cohorts of institutional data. [7],[8] Most of the published data do not include information on all the variables including association of any adverse genetic mutations. This study is based on a series of 35 patients of DTC with I-131 avid distant metastasis wherein most of the patients were managed by total/near total thyroidectomy, followed by I-131 ablation and thyroxine suppression. We have made an attempt to identify clinical variables that may have an influence on the survival in such patients. The study did not include patients with elevated serum Tg and negative diagnostic I-131 whole body scan (I-131 D X WBS).


   Materials and methods Top


This is a retro-prospective study of 5 years from 2008 to 2013 conducted at Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, a 600 bed tertiary care teaching hospital in the Northern mountainous state of Jammu and Kashmir in India. The study was approved by the hospital ethics committee. 463 patients (362 females, 101 males,) with histopathologically proven DTC who attended the Department of Nuclear Medicine at SKIMS were studied. American Joint Cancer Committee/Union Internationale Contre le Cancer histological classification of thyroid cancer was used to assign tumor (T) and regional lymph node (N) status. [9] Of the 463 patients with DTC 35 patients (26 females, 9 males) who had distant metastasis at presentation were included for further analysis in this study. Only such lesions were considered metastasis of DTC, which on endogenous thyroid stimulating hormone (TSH) stimulated low dose (1-3 mCi) I-131D X WBS or I-131 posttherapy (I-131R X WBS) done within 1-week of therapy revealed nonphysiological uptake of I-131 at sites other than neck. The I-131D X WBS/I-131R X WBS in retrospectively studied patients were reviewed individually by two Nuclear medicine physicians before inclusion in the study. All the prospectively studied patients were subjected to a TSH stimulated I-131D X WBS at 4-6 weeks after thyroid cancer surgery. I-131D X WBS scans were done after ensuring stimulated TSH levels of >30 mIU/L. Planar whole body images on a dual head gamma camera were acquired at 72 h post-I-131 administration. Anterior and posterior whole body images were obtained in a continuous mode. Additional single photon computerized tomography (SPECT) images were acquired in selected cases for better anatomical correlation. Some of the prospectively studied patients also underwent additional correlative imaging procedures such as X-ray, CT scans of relevant I-131 avid lesions.

Image interpretation

Planar whole body and SPECT images were analyzed by two Nuclear medicine physicians who were blinded to each others findings. Only distant nonphysiological I-131 uptake was considered as metastasis from DTC. In doubtful lesions additional imaging procedures such as X-ray, CT scans were done, and subsequent consensus decisions between the two nuclear physicians arrived at.

Iodine-131 therapy and follow-up

Patients who revealed distant metastasis or neck uptake on I-131D X WBS were considered for administration of therapeutic I-131. A mean dose of 92 mCi (range 90-180 mCi) was administered in 31 patients (4 patients did not report though they were advised). Patients were followed-up at 6 months with clinical examination, neck ultrasonography, TSH suppressed serum Tg levels. Patients with Tg levels of >5 ng/ml and/or significant cervical lymphadenopathy underwent a repeat TSH stimulated I-131D X WBS. All other patients were subjected to a TSH stimulated annual I-131D X WBS. Patients of DTC with distant metastasis were put on suppressive doses of levothyroxine (LT4) to maintain a TSH level below 0.1 mIU/L. [4]

Statistical methods

The statistical analysis was done using the SPSS 20 statistical package from Windows SPSS, Inc., Chicago, IL, USA. [10],[11] Univariate analysis of various variables such as gender, age, tumor (T) stage, Regional lymph node status (N) stage, histopathology, metastatic site, type of surgery, I-131 administration was done using the Log rank test. Variables found statistically significant for cause-specific survival were further subjected to multivariate analysis using Cox proportional hazards model. Kaplan-Meir method was used to draw the survival curves from initial presentation to the last follow-up or time of death. P < 0.05 was considered significant.


   Results Top


A summary of the clinical characteristics of the patients of DTC with metastasis is given in [Table 1]. Thirty-five (7.5%) patients out of total 463 patients of DTC (papillary 420, follicular 37, Hurthle cell 5, poorly differentiated 1) who attended Nuclear Medicine Department had distant metastasis at presentation. The mean age of the patients in the study group was 41.4 years. Eighteen (51.4%) patients were in the age group of 45 years or less. There were 26 (74.2%) female patients with a mean age of 41.2 years (range 11-70 years) and 9 (24.71%) male patients with a mean age of 35.11 years (range 13-55 years). The majority of 32 (91.4%) underwent total/near total thyroidectomy and 3 (8.6%) of patients had incomplete surgeries. The DTC with distant metastasis were classified in 23 (65.7%) as papillary thyroid carcinoma (PTC), 11 (31.4%) as follicular thyroid carcinoma (FTC) and 1 (2.9%) as poorly DTC (PDTC). The tumors were classified as T1-T2 in 23 (65.7%) patients and T3-T4 in 12 (34.3%) patients. The regional lymph node status was N0 in 4 (11.4%) patients, N1 in 19 (54.3%) patients and NX in 12 (34.3%) patients. Bone was the most common single site of metastasis in 15 (42.85%) patients, followed by lung in 14 (40%) patients. Multiple site metastasis involving lung and bone were present in 4 (11.42%) patients, brain and bone in 1 (2.85%) patient and lung, brain and bone in 1 (2.85%) patient. Overall single organ metastasis was present in 29 (82.9%) patients and multiple organ metastases in 6 (17.1%) patients. Frequency of organ metastasis varied among the histological subtypes of DTC [Table 2]. Among the 23 patients with PTC, 11 (47.82%) patients had lung metastasis, 8 (34.78%) patients had bone metastasis, 4 (17.39%) had metastasis in lung and bone. Among the 11 patients with FTC, 7 (63.63%) patients had bone metastasis, 3 (27.27%) patients had lung metastasis and 1 (9.09%) had metastasis in lung, brain and bone. One patient with PDTC had metastasis involving the multiple sites of brain and bone 31 (88.6%) patients were administered a mean I-131 therapeutic dose of 92 mCi (range 90-180 mCi). Four (11.4%) patients did not receive therapeutic I-131, as they did not report back for the scan. Of the 31 patients who received therapeutic I-131, 25 patients were evaluated for response at 1-year. Five patients died of disease before completion of 1-year and 1-patient did not report for follow-up at 1-year. Guidelines from RECIST 1.1 were followed to assess the response. [12] Twelve (48%) patients had a complete response 2 (8%) patients had partial response, 9 (36%) patients had stable disease, 2 (8%) patients had progressive disease. The overall response rate to therapeutic I-131 was 56%. The overall survival at 5 years was 26 (74.3%) patients. Based on their death certificates and the clinical status preceding their deaths cumulative cause-specific death occurred in 9 (25.7%) patients by 5 years. [Table 3] summarizes the univariate analysis of cause-specific survival variables such as patient characteristics, tumor characteristics, and treatment modalities. On univariate analysis age over 45 years, advanced tumor stage (T3-T4) and regional nodal metastasis (N1), tumor histology (FTC and PDTC) were associated with poor survival at 5 years (P < 0.05). Nonadministration of therapeutic I-131 after thyroid surgery was associated with poor survival (P < 0.05). Multivariate analysis of variables significant on univariate analysis [Table 4] revealed a poor survival in advanced tumor stage (T3-T4) and nonadministration of therapeutic I-131 after thyroid surgery (P < 0.05).
Table 1: Clinical characteristics of patients


Click here to view
Table 2: Metastatic sites and histopathology


Click here to view
Table 3: Cause specific survival (univariate analysis)


Click here to view
Table 4: Cause specific survival: Multivariate analysis


Click here to view



   Discussion Top


Differentiated thyroid cancer has a relatively better prognosis in terms of overall and disease free survival. Adequate surgery, I-131 thyroid remnant ablation, and TSH suppression with calibrated doses of thyroxine coupled with carefully designed follow-up strategy have also made an incremental impact to the improved survival and stabilization of this disease. [13],[14] Distant metastasis in DTC adversely effects the survival and quality of life in these patients. [13],[14],[15],[16],[17] Published data on variables having an impact on survival in patients of DTC with distant metastasis is scarce. The results of the few published series fail satisfactory comparison due to inconsistencies in the management protocol particularly the extent of surgery and postoperative administration of ablative/therapeutic dose of I-131. The criteria for categorizing patients of DTC into low risk and high risk are not universally agreed and practiced upon. [18] The optimal management of DTC patients with elevated serum Tg level and a negative I-131D X WBS (TENIS) continues to be debated. [19] The advent and availability of PET tracers and imaging notably F-18 FDG PET have opened new management options in patients of advanced DTC who's natural history does not conform to a predictable course. [20] As of today surgery, and I-131 continue to be the mainstream treatment options in the management of metastatic DTC. The present study though based on a smaller number of metastatic DTC patients with a limited follow-up period was undertaken with an objective to understand the early course of metastatic DTC. Whereas interpreting our results, we made an attempt at comparative analysis with two of the published studies based on reasonably sufficient data on various clinical variables. [6],[7] These observations are summarized in [Table 5] [Table 6] [Table 7]. In our study, 7.5% of patients with DTC had distant metastasis at presentation. This is comparable to some of the published studies, which report an incidence of 8-23% distant metastasis in patients of DTC. [7],[8] One of the earlier studies from Royal Marsden hospital, London reported an incidence of 7.2% for distant metastasis in DTC. [7] This study is based on 1536 patients from 1942 to 2002. Distant metastasis in this study was defined by various clinical and/or radiographic evidence at presentation. I-131 avid metastasis was also included in the later period of this study. It is quite possible that some of the metastatic lesions documented in the earlier period of this study were not metastatic as no biopsy details were provided. In our study, only I-131 avid distant nonphysiological uptake was defined as metastasis. We do not think our incidence of 7.5% distant metastasis in DTC though similar to the Royal Marsden study is comparable as different criteria have been used to define metastasis. The similarity of incidence in our and Royal Marsden study is a coincidence. Moreover, we have not included TENIS patients in our study, the results of which are likely to modify our reported 7.5% incidence of distant metastasis in DTC. In our study 23 (5.47%) of 420 patients with PTC had distant metastasis in comparison to 7% reported in a study from the Mayo Clinic. [6] Eleven (29.72%) of 37 patients with FTC in our had distant metastasis, which is more when compared to 19% in the Mayo Clinic study. The mean age at presentation in our study was lower at 41.44 years when compared to the reported mean age of 56 years in the Royal Marsden study. The mean age of 41.22 years among female patients and 35.11 years among the male patients in our study are also less than the reported study from Royal Marsden Hospital. Bone was the most common organ site of metastasis in our study in 15 (42.85%) patients. This is in contrast to the 24% incidence of bone metastasis in the Royal Marsden study and 20% in Mayo Clinic study. Lung metastasis was seen in 14 (40%) patients in our study, which is less than that of Royal Marsden and Mayo Clinic studies. Bone and lung constitute the most common single organ sites of metastasis in our study, and this observation is consistent with the reported figures of 73% in Royal Marsden and Mayo Clinic studies. On the analysis of metastatic sites with respect to histopathology, bone was the most common single site of metastasis in 7 (63.63%) patients of FTC. Relative abundance of bone metastasis in FTC has also been reported in the Mayo Clinic study. Multiple metastatic organ involvement in the present study was observed in 6 (17.14%) patients that are slightly <19-30% reported in the published data. [7],[8] The cumulative cause-specific death rate in our study was 25.71% at 5 years which is certainly better than 58% in the Mayo Clinic study and the overall death rate of 64% reported in Royal Marsden study. [8] This difference can be explained by the time periods of Mayo clinic study (1940-1970) and Royal Marsden study (1940-2002). During the early periods of these studies, the routine use of I-131 in DTC was in its evolutionary stages, and the type of surgery performed for DTC also varied considerably. In the Royal Marsden study, I-131 ablation and therapy was not administered to 23.32% and 33.33% patients, respectively. In the same study, only 53.85% of patients underwent a definitive surgery for DTC. 56.75% of patients in this study had advanced tumors with T3-T4 tumor stage, and 53.15% had a regional nodal status of N1. In our study, an advanced tumor stage of T3-T4 was seen in 34.28%. Our study reflects a better management protocol and subsequent results on account of surgical completeness in 91.42% of patients and near universal use of I-131 ablation/therapy in 89% of patients. On univariate analysis higher T stage, (T3-T4) and N1 regional nodal status found to have a significant impact on cause-specific survival in our study were at variance with the published data. Significant effect of age more than 45 years in the present study is consistent with a similar observation made in the Royal Marsden study. The Royal Marsden study also observed an increasing hazards ratio with increasing age beyond 45 years, which is understandable. The significant impact of tumor histopathology of FTC and PDTC observed in our study were consistent with similar observations reported in the Royal Marsden study but at variance with the Mayo Clinic study which revealed an insignificant impact of histopathology on survival in DTC with distant metastasis. A significant impact of postsurgical I-131 ablation/therapy seen in our study is similar to the observations made in the Mayo Clinic study. On multivariate analysis, our study found a significant impact of the advanced T stage of the tumor and I-131 administration for remnant ablation and/or treatment on survival. In our study, the details about the tumor grade were not available. An interesting observation was made about the significance of period of presentation in the Royal Marsden study. The hazard ratio (95% confidence interval) in that study fell from 1 in the period before 1970-0.17 for the period of 1991-2002 reflecting a survival advantage over the years as the treatment options for DTC with metastasis got refined in terms of improved surgery, I-131 treatment, and thyroxine suppression. We have probably reached a level of expertise and experience in the management of DTC with or without metastasis where the overall prognosis and survival is expected to improve more with the passage of time.
Table 5: Clinical data


Click here to view
Table 6: Survival


Click here to view
Table 7: Cause specific survival-Univariate and Multivariate analysis


Click here to view


Limitations of the study

Considering the long natural history of DTC, our study is based on a relatively limited follow-up period and comprises a smaller number of patients. The results are likely to alter in a larger sample with longer follow-up period. The metastatic lesions are based on the findings of nonphysiological I-131 uptake without histopathological confirmation. The entire spectrum of histopathology and the subtypes in DTC are not represented in the study sample. The tumor grades are not mentioned. The patients have not undergone the molecular studies for gene mutations. TENIS patients are not included in the study, which is likely to alter the results to some extent. Our study is an institution based one and is likely to suffer from selection bias inherent in such studies.


   Conclusion Top


The multivariate analysis in our study reveals an improved survival in patients of DTC with distant metastasis who have an early stage (T1-T2) and those ablated/treated with I-131 supplemented with TSH suppressive dose of thyroxine. On Univariate analysis, younger patients (≤45 years) with the more common papillary histopathology without regional lymph node involvement have better survival rates. In comparison to previously published data, the 5 years cause-specific mortality is much less in our study, which is attributable to uniformity in treatment protocol including the universal use of I-131 for remnant ablation/treatment of metastasis. A prospective long-term follow-up study in patients of DTC with distant metastasis based on a large sample size is likely to influence these interim results. The recent encouraging results of some of the novel therapies like tyrosine kinase inhibitors in advanced thyroid cancers need more validation, nevertheless these developments offer hope in patients of advanced thyroid cancer who otherwise are refractory to standard treatment options.

 
   References Top

1.
Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide increasing incidence of thyroid cancer: Update on epidemiology and risk factors. J Cancer Epidemiol 2013;2013:965212.  Back to cited text no. 1
    
2.
Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al., editors. SEER Cancer Statistics Review 1975-2011. Bethesda, MD: National Cancer Institute; 2014. Based on November 2013 SEER Data Submission, Posted to the SEER. Available from: http://www.seer.cancer.gov/csr/1975_2011. [Last accessed on 2015 Mar 25].  Back to cited text no. 2
    
3.
Thyroid Cancer Page. National Cancer Institute. Available from: http://www.cancer.gov/cancer topics/types/thyroid. [Last revised on 2015 Mar 25].  Back to cited text no. 3
    
4.
American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-214.  Back to cited text no. 4
    
5.
Pacini F, Castagna MG, Brilli L, Pentheroudakis G, ESMO Guidelines Working Group. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23 Suppl 7:vii110-9.  Back to cited text no. 5
    
6.
Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, et al. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: The M. D. Anderson experience. J Clin Endocrinol Metab 2010;95:2588-95.  Back to cited text no. 6
    
7.
Haq M, Harmer C. Differentiated thyroid carcinoma with distant metastasis at presentation: Prognostic factors and outcome. Clin Endocrinol 2005;63:87-93.  Back to cited text no. 7
    
8.
Ruegemer JJ, Hay ID, Bergstralh EJ, Ryan JJ, Offord KP, Gorman CA. Distant metastases in differentiated thyroid carcinoma: A multivariate analysis of prognostic variables. J Clin Endocrinol Metab 1988;67:501-8.  Back to cited text no. 8
    
9.
Lang B, Lo CY, Chan WF, Lam KY, Wan KY. Restaging of differentiated thyroid carcinoma by the sixth edition AJCC/UICC TNM staging system: Stage migration and predictability. Ann Surg Oncol 2007;14:1551-9.  Back to cited text no. 9
    
10.
IBM Corp. Released 2011. IBM SPSS Statistics for Windows, Version 20.0. Armonk, New York; IBM Corp.; 2011.  Back to cited text no. 10
    
11.
Cox DR. Regression models and life tables. J R Stat Soc 1972;34:187-220.  Back to cited text no. 11
    
12.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.  Back to cited text no. 12
    
13.
Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-28.  Back to cited text no. 13
    
14.
Vini I, Harmer C. Thyroid. In: Price P, Sikora K, editors. Treatment of Cancer. London: Arnold; 2002. p. 401-27.  Back to cited text no. 14
    
15.
Pelikan DM, Lion HL, Hermans J, Goslings BM. The role of radioactive iodine in the treatment of advanced differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 1997;47:713-20.  Back to cited text no. 15
    
16.
Schlumberger M, Tubiana M, De Vathaire F, Hill C, Gardet P, Travagli JP, et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 1986;63:960-7.  Back to cited text no. 16
    
17.
Shaha AR, Shah JP, Loree TR. Differentiated thyroid cancer presenting initially with distant metastasis. Am J Surg 1997;174:474-6.  Back to cited text no. 17
    
18.
Papaleontiou M, Haymart MR. New insights in risk stratification of differentiated thyroid cancer. Curr Opin Oncol 2014;26:1-7.  Back to cited text no. 18
    
19.
Sfar R, Kamoun T, Nouria M, Regaieg H, Ammar N, Charfi H, et al. Differentiated thyroid cancer with thyroglobulin elevation and negative iodine scintigraphy (TENIS syndrome). Int J Otolaryngol Head Neck Surg 2014;3:149-53.  Back to cited text no. 19
    
20.
Bertagna F, Bosio G, Biasiotto G, Rodella C, Puta E, Gabanelli S, et al. F-18 FDG-PET/CT evaluation of patients with differentiated thyroid cancer with negative I-131 total body scan and high thyroglobulin level. Clin Nucl Med 2009;34:756-61.  Back to cited text no. 20
    



 
 
    Tables

  [Table 1], [Table 2], [Table 3], [Table 4], [Table 5], [Table 6], [Table 7]



 

Top
  
 
  Search
 
  
    Similar in PUBMED
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    Abstract
   Introduction
    Materials and me...
   Results
   Discussion
   Conclusion
    References
    Article Tables

 Article Access Statistics
    Viewed1426    
    Printed31    
    Emailed0    
    PDF Downloaded117    
    Comments [Add]    

Recommend this journal